Please assess the completion status of the following clinical trial:

Trial Title: RHA® 4 With New Anesthetic - Nasolabial Folds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatient, male or female of any race, 22 years of age or older. Female subjects of childbearing potential must have a negative UPT at Visit 1 and practice a reliable method of contraception throughout the study.~2. Moderate to severe bilateral nasolabial folds (grade 3 or 4 on the five-point WSRS).~3. Nasolabial folds of the same WSRS grade on the left and right sides of the face.~4. Able to follow study instructions and complete all required visits.~5. Sign the IRB-approved ICF, Photographic Release Form, the Authorization for Use and release of Health and Research Study Information (HIPAA) form, and if applicable the California Experimental Research Subject's Bill of Rights prior to any study-related procedures being performed.~Exclusion Criteria:~1. Female subjects who are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.~2. Known hypersensitivity or previous allergic reaction to any component of the study devices.~3. Use of a prohibited treatment/procedure within time periods defined in the protocol~4. Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.~5. History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study.~6. History of connective tissue disease.~7. Malignancy (excluding non-melanoma skin cancer) within the past 5 years.~8. History of skin cancer in the treatment area.~9. Clinically active disease or infection in the NLF area.~10. Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results or compliance of the subject and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.~11. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.~12. Exposure to any other investigational drug/device within 90 days of entering the study.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RHA®4 with new anesthetic agent (Type: EXPERIMENTAL): Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side.
- RHA®4-Lidocaine (Type: EXPERIMENTAL): Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side.

Based on this trial design, predict the completion outcome and termination type (if applicable).